[1] Andrea S, NERLICH G, ERWIN D. N-(carboxymethyl)lysine in atherosclerotic vascular lesions as a marker for local oxidative stress, 1999
[2] Kislinger T, FU C F, HUBER B. Nε-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. 1999(44). doi:10.1074/jbc.274.44.31740
[3] Nagai R, IEDA K, KAWASAKI Y. Conversion of amadori product of maillard reaction to Nepsilon-(carboxymethyl)lysine condition. 1998(2). doi:10.1016/S0014-5793(98)00263-4
[4] SCHLEICHER E D, WAGNER E, NERLICH A G. Increased accumulation of the glycoxidation product N (epsilon)-( carboxymethyl)lysine in human tissues in diabetes and aging. 1997(3). doi:10.1172/JCI119180
[5] MAHTAB U, SUZANNE R, JOHN W. Identification of Nε(carboxymethyl) lysine as a degradation product of fructoselysine in glycated protein, 1986(11)
[6] Horie K, MIYATA H, MAEDA K. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. 1997(12). doi:10.1172/JCI119853
[7] ANTONIO E N, ANA M J, FREIRE P. A quantitative modelof the generation of Nε-(carboxymethyl)lysine in the maillard reaction between collagen and glucose. 2003(part 2). doi:10.1042/BJ20030098
[8] Fu M X, BLACKLEDG T J, BAYNES J W. Glycarion,glycosylation,and cross-linking of collagen by glucose:kinetics,mechanism,and inhibition of the late stages of the maillard reaction. 1994. doi:10.2337/diabetes.43.5.676
[9] Fu M X, JESUS R, ALICIA J. The advanced glycation end product, Nε-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. 1996(17). doi:10.1074/jbc.271.17.9982
[10] WELIS-KNECHT K J, ZYZAK D V, LITCHFIELD J E. Mechanism of autoxidative glycosylation:identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. 1995(11). doi:10.1021/bi00011a027
[11] ELGAWISH A, GLOLMB M, FRIEDLANDER M. Involvement of hydrogen peroxide in collagen cross-linking by high glucose in vitro andin vivo. 1996
[12] Reddy S, BICHER J N, KEVIN J. Nε-(carboxymethyl)lysine Is a dominant advanced glycation end product (AGE) antigen in tissue proteins. 1995(34). doi:10.1021/bi00034a021
[13] GLARDINO I, EDELSTEIN D, BROWNLEE M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. 1994. doi:10.1172/JCI117296
[14] Anderson M M, RQUENA J R, CROWLEY J R. The myeloperoxidase system of human phagocytes generates Nepsilon(carboxymethyl) lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. 1999(1). doi:10.1172/JCI3042
[15] REQUENA J R, FU M X, AHMED M U. Lipoxidation products as biomarkers of oxidative damage to protein during lipid peroxidation reactions, 1996
[16] Ikeda K, HIGASHI T, JINNOUCHI Y. Nε-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. 1996. doi:10.1021/bi9530550
[17] Xia L, SAKASHITA N, NAGAI R. Immunohistochemical distribution and subcellular localizaiton of three distribution and subcellular localization of three distinct specific molecular structures of advanced glycation end products in human tissues. 1998(12)
[18] Schmidt A M, VIANNA M, GERlACH M. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface, 1992
[19] WUTER J L, ZOUKOURIAN C, CHAPPEY O. Receptormediated endothelial cell dysfunction in diabetic vasculopathy.Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. 1996(1). doi:10.1172/JCI118397
[20] PARK L, RAMAN K G, LEE, KJ. Suppression pf accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. 1998
[21] Singh R, BARDEN A, MORI T. Advanced glycation end-products:a review. 2001. doi:10.1007/s001250051591
[22] Kobayashi S, SHINOHARA H, TSUNEKI H. N(epsilon)-(Carboxymethyl)lysine proliferated CD34( + ) cells from rat choroidal explant in culture, 2004
[23] WAUTIER M P, MASSIN P, GUILLAUSSEAU P J. Nε(carboxymethyl) lysine as a biomarker for microvascular complica-tions in type 2 diabetic patients. 2003(1). doi:10.1016/S1262-3636(7)70006-X
[24] SHIBAYAMA R, ARAKI N, NAGAI R. Autoantibody against Nε-(carboxymethyl) lysine an advanced glycation end product of the maillard reaction. 1999(9). doi:10.2337/diabetes.48.9.1842
[25] Miyata T, WADA Y, CAIZ. Implication of an increasedoxidative stress in the formation of advanced glycation end products in patients with end-stnge renal failure. 1997. doi:10.1038/ki.1997.160
[26] Sakata N, IMANAGA Y, MENG J. Immunohistochemical localization of different epitopes of advanced glycation end products in human atherosclerotic lesions. 1998. doi:10.1016/S0021-9150(98)00149-X
[27] HAMEHN M, BOROT-LALOT C, FRIGUET B. Increased level of glycoxidation product Nε-(carboxymethyl)lysine in rat serum and urine proteins with aging:link with glycoxidative damage accumulation in kidney. 2003(2). doi:10.1016/S0003-9861(2)00735-X
[28] Dei R, TALEDA A, NIWA H. Lipid peroxidation and advanced glycation end products in the brain in normal aging and in Alzheimer' s disease. 2002(2). doi:10.1007/s00401-002-0523-y
[29] USEUGI N, SAKATA N, NAGAI R. Glycoxidative modification of AA amyloid deposits in renal tissue. 2000
[30] BAR K J, FRANKE S, WENDA B. Pentosidine and Nε(carboxymethyl) lysine in Alzheimer' s disease and vascular dementia. 2003(2). doi:10.1016/S0197-4580(2)00086-6
[31] FRANKRE S, MUILER A, SOMMER M. Serum levels of total homocysteine,homocysteine metabolites and of advanced glycation end-products(AGEs) in patients after renal transplantation. 2003
[32] THORSTEN P, GRASS L, REDDY S. The serum concentration of the advanced glycation end-product Nepsilon-(carboxymethyl) lysine is increased in uremia, 1997 |
